About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
SMART QUOTES
Smart
Quotes
Ajanta Pharma Ltd.
Industry :
Pharmaceuticals & Drugs
BSE Code
532331
ISIN Demat
INE031B01049
Book Value
350.00
NSE Code
AJANTPHARM
Dividend Yield %
0.98
Market Cap
356360.13
P/E
37.79
EPS
75.48
Face Value
2
BSE
NSE
06-Feb-2026
BSE
NSE
NSE F & O
06-Feb-2026
BSE
NSE
NSE F & O
Last Price
2852.35
Net Change
40.05
% Change
1.42%
Prev.Close
2812.30
Open
2817.30
High
2860.50
Low
2789.85
Volume
1311
Last Price
2852.70
Net Change
35.4
% Change
1.26%
Prev.Close
2817.30
Open
2828.30
High
2866.00
Low
2788.00
Volume
107572
Value
3695100
Best Buy
0.00
Best Sell
0.00
Best Quantity
0
Sell Quantity
0
Today's Range
2860.50
52-Week High
3020.45
52-Week Low
2022.05
Value
304578536.7
Best Buy
0.00
Best Sell
2852.70
Best Quantity
0
Sell Quantity
14
Today's Range
2866.00
52-Week High
3020.80
52-Week Low
2327.30
Open Price
High Price
Low Price
Last Price
Prev Close
Change
% Change
Average Price
Underlying Value
Number of contracts traded
Turnover in Rs. Lakhs
Open Interest
Change in O I
% Change in O I
%
Today
|
1W
|
1M
|
1Y
You need to upgrade your Flash Player
Best Bid
Best Offer
Quantity
0
Price
0.00
Quantity
0
Price
0.00
Best Bid
Best Offer
Quantity
0
Price
0.00
Quantity
14
Price
2852.70
Best Bid
Best Offer
Quantity
Price
Quantity
Price
Holding Details
More
Latest Corporate Events
Bonus
1 : 2
22-Jun-22
Book Closure
23-Jul-20
30-Jul-20
Dividend
1400 %
10-Nov-25
Company News
05-02-2026
Ajanta Pharma informs abo...
02-02-2026
Ajanta Pharma informs abo...
02-02-2026
Ajanta Pharma informs abo...
30-01-2026
Intimation Of Vesting An...
13-01-2026
Ajanta Pharma incorporate...
12-01-2026
Ajanta Pharma informs ab...
24-12-2025
Ajanta Pharma enters into...
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Smart ODR Portal
|
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
|
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
|
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
|
Details of Research Analyst
|
UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.
